Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V.

J Clin Oncol. 2019 Mar 20;37(9):714-722. doi: 10.1200/JCO.2018.78.7986. Epub 2019 Feb 5.

PMID:
30721110
2.

Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition.

Vaklavas C, Zinn KR, Samuel SL, Meng Z, Grizzle WE, Choi H, Blume SW.

Oncol Rep. 2018 Jun;39(6):2482-2498. doi: 10.3892/or.2018.6332. Epub 2018 Mar 23.

3.

Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.

Vaklavas C, Blume SW, Grizzle WE.

Front Oncol. 2017 Jul 26;7:158. doi: 10.3389/fonc.2017.00158. eCollection 2017. Review.

4.

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.

Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ.

Oncotarget. 2017 Feb 28;8(9):16052-16074. doi: 10.18632/oncotarget.14109. Review.

5.

IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells.

Vaklavas C, Grizzle WE, Choi H, Meng Z, Zinn KR, Shrestha K, Blume SW.

Tumour Biol. 2016 Oct;37(10):13247-13264. Epub 2016 Jul 26.

6.

Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.

Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE.

Cancer Immunol Res. 2016 May;4(5):390-9. doi: 10.1158/2326-6066.CIR-15-0243. Epub 2016 Mar 15.

7.

Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?

Morris GJ, Dawood S, Cortes J, Ward JH, Vaklavas C, Forero A, Ward S, Toppmeyer D.

Semin Oncol. 2015 Aug;42(4):e67-79. doi: 10.1053/j.seminoncol.2015.07.001. Epub 2015 Jul 6. Review. No abstract available.

PMID:
26320071
8.

Small molecule inhibitors of IRES-mediated translation.

Vaklavas C, Meng Z, Choi H, Grizzle WE, Zinn KR, Blume SW.

Cancer Biol Ther. 2015;16(10):1471-85. doi: 10.1080/15384047.2015.1071729. Epub 2015 Jul 15.

9.

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.

Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC).

Clin Cancer Res. 2015 Jun 15;21(12):2722-9. doi: 10.1158/1078-0432.CCR-14-2780. Epub 2015 Mar 16.

10.

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.

Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF; Translational Breast Cancer Research Consortium (TBCRC).

Clin Cancer Res. 2015 Jun 15;21(12):2771-9. doi: 10.1158/1078-0432.CCR-14-2781. Epub 2015 Mar 16.

11.

Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience.

Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R.

Hepatogastroenterology. 2013 Oct;60(127):1611-23.

PMID:
24634931
12.

Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).

Vaklavas C, Forero A.

BioDrugs. 2014 Jun;28(3):253-63. doi: 10.1007/s40259-014-0085-2. Review.

PMID:
24496926
13.

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Vaklavas C, Forero-Torres A.

Ther Adv Hematol. 2012 Aug;3(4):209-25. doi: 10.1177/2040620712443076.

14.

A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer.

Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, Forero A, Ravi V, Patel S, Boudadi K, Chugh R, Morris GJ.

Semin Oncol. 2013 Apr;40(2):135-44. doi: 10.1053/j.seminoncol.2013.01.010. No abstract available.

PMID:
23540738
15.

Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.

Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A.

Cancer Biother Radiopharm. 2013 Jun;28(5):370-9. doi: 10.1089/cbr.2012.1387. Epub 2013 Mar 26.

PMID:
23530878
16.

By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes.

Vaklavas C, Ross JR, Nabell LM, Forero A, Heslin MJ, Wood TE.

J Natl Compr Canc Netw. 2012 Jan;10(1):7-13.

PMID:
22223865
17.

How do I treat "triple-negative" disease.

Vaklavas C, Forero-Torres A.

Curr Treat Options Oncol. 2011 Dec;12(4):369-88. doi: 10.1007/s11864-011-0168-y.

PMID:
22048876
18.

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.

Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R.

Cancer. 2012 Mar 1;118(5):1422-8. doi: 10.1002/cncr.26413. Epub 2011 Aug 5.

19.

A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogenetics.

Vaklavas C, Steciuk MR, Ren Y, Baird MF, Mikhail FM, Foran JM.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):521-4. doi: 10.1016/j.clml.2011.03.036. Epub 2011 May 19. No abstract available.

PMID:
21729689
20.

Common cardiovascular medications in cancer therapeutics.

Vaklavas C, Chatzizisis YS, Tsimberidou AM.

Pharmacol Ther. 2011 May;130(2):177-90. doi: 10.1016/j.pharmthera.2011.01.009. Epub 2011 Jan 26. Review.

PMID:
21277894
21.

The changing perspective of cardiology in cancer care.

Vaklavas C, Chatzizisis YS.

Expert Rev Cardiovasc Ther. 2011 Jan;9(1):1-3. doi: 10.1586/erc.10.162. No abstract available.

PMID:
21166523
22.

Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.

Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM.

Virol J. 2010 Sep 28;7:256. doi: 10.1186/1743-422X-7-256.

23.

Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience.

Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R.

Cancer. 2011 Jan 1;117(1):77-85. doi: 10.1002/cncr.25346. Epub 2010 Aug 24.

24.

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD.

Drug Saf. 2010 Mar 1;33(3):171-87. doi: 10.2165/11319380-000000000-00000. Review.

PMID:
20158283
25.

Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.

Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ.

Clin Cancer Res. 2010 Feb 15;16(4):1149-58. doi: 10.1158/1078-0432.CCR-09-2416. Epub 2010 Feb 9.

26.

Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM.

Oncologist. 2010;15(2):130-41. doi: 10.1634/theoncologist.2009-0252. Epub 2010 Feb 5. Review.

27.

Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.

Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R.

J Clin Endocrinol Metab. 2009 Nov;94(11):4423-32. doi: 10.1210/jc.2009-0743. Epub 2009 Oct 9.

28.

Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.

Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ.

J Pediatr Hematol Oncol. 2009 Nov;31(11):803-11. doi: 10.1097/MPH.0b013e3181ba43dc.

PMID:
19801947
29.

Molecular basis of statin-associated myopathy.

Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD.

Atherosclerosis. 2009 Jan;202(1):18-28. doi: 10.1016/j.atherosclerosis.2008.05.021. Epub 2008 May 21. Review.

PMID:
18585718
30.

Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy?

Chatzizisis YS, Vaklavas C, Giannoglou GD.

Am J Cardiol. 2008 Apr 1;101(7):1071. doi: 10.1016/j.amjcard.2007.12.005. No abstract available.

PMID:
18359340
31.

'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.

Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A.

Leuk Res. 2007 May;31(5):691-4. Epub 2006 Nov 13.

PMID:
17095087
32.

Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin grafts.

Christakis C, Vaklavas C, Kontos N, Chatzidimitriou C, Tzelepi K, Karanikas M, Christakis E.

Tech Coloproctol. 2004 Nov;8 Suppl 1:s85-8.

PMID:
15655654

Supplemental Content

Loading ...
Support Center